188 related articles for article (PubMed ID: 36853374)
1. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich
Dorman K; Zhang D; Heinrich K; Reeh L; Weiss L; Haas M; Beyer G; Rössler D; Goni E; Renz BW; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
Target Oncol; 2023 Mar; 18(2):257-267. PubMed ID: 36853374
[TBL] [Abstract][Full Text] [Related]
2. Lessons learned: the first consecutive 1000 patients of the CCCMunich
Heinrich K; Miller-Phillips L; Ziemann F; Hasselmann K; Rühlmann K; Flach M; Biro D; von Bergwelt-Baildon M; Holch J; Herold T; von Baumgarten L; Greif PA; Jeremias I; Wuerstlein R; Casuscelli J; Spitzweg C; Seidensticker M; Renz B; Corradini S; Baumeister P; Goni E; Tufman A; Jung A; Kumbrink J; Kirchner T; Klauschen F; Metzeler KH; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 May; 149(5):1905-1915. PubMed ID: 35796778
[TBL] [Abstract][Full Text] [Related]
3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
4. A Retrospective Analysis of Biliary Tract Cancer Patients Presented to the Molecular Tumor Board at the Comprehensive Cancer Center Munich.
Zhang D; Dorman K; Heinrich K; Weiss L; Boukovala M; Haas M; Greif PA; Ziemann F; Beyer G; Roessler D; Goni E; Renz B; D'Haese JG; Kunz WG; Seidensticker M; Corradini S; Niyazi M; Ormanns S; Kumbrink J; Jung A; Mock A; Rudelius M; Klauschen F; Werner J; Mayerle J; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
Target Oncol; 2023 Sep; 18(5):767-776. PubMed ID: 37594677
[TBL] [Abstract][Full Text] [Related]
5. NGS-guided precision oncology in metastatic breast and gynecological cancer: first experiences at the CCC Munich LMU.
Sultova E; Westphalen CB; Jung A; Kumbrink J; Kirchner T; Mayr D; Rudelius M; Ormanns S; Heinemann V; Metzeler KH; Greif PA; Burges A; Trillsch F; Mahner S; Harbeck N; Wuerstlein R
Arch Gynecol Obstet; 2021 May; 303(5):1331-1345. PubMed ID: 33277683
[TBL] [Abstract][Full Text] [Related]
6. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxaliplatin (GEMOXCET) in first-line therapy.
Kullmann F; Hartmann A; Stöhr R; Messmann H; Dollinger MM; Trojan J; Fuchs M; Hollerbach S; Harder J; Troppmann M; Kutscheidt A; Endlicher E
Oncology; 2011; 81(1):3-8. PubMed ID: 21894049
[TBL] [Abstract][Full Text] [Related]
7. Using next-generation sequencing to determine potential molecularly guided therapy options for patients with resectable pancreatic adenocarcinoma.
Wright GP; Chesla DW; Chung MH
Am J Surg; 2016 Mar; 211(3):506-11. PubMed ID: 26754455
[TBL] [Abstract][Full Text] [Related]
8. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
[TBL] [Abstract][Full Text] [Related]
9. Pancreatic adenocarcinomas without KRAS, TP53, CDKN2A and SMAD4 mutations and CDKN2A/CDKN2B copy number alterations: a review of the genomic landscape to unveil therapeutic avenues.
Voutsadakis IA; Digklia A
Chin Clin Oncol; 2023 Feb; 12(1):2. PubMed ID: 36922358
[TBL] [Abstract][Full Text] [Related]
10. Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF; Ye Z; Qin Y; Xu XW; Yu XJ; Zhuo QF; Ji SR
Acta Pharmacol Sin; 2021 Nov; 42(11):1725-1741. PubMed ID: 33574569
[TBL] [Abstract][Full Text] [Related]
11. Kirsten Rat Sarcoma Viral Oncogene Homologue (KRAS) Mutations in the Occurrence and Treatment of Pancreatic Cancer.
Zhu Z; Xiao S; Hao H; Hou Q; Fu X
Curr Top Med Chem; 2019; 19(23):2176-2186. PubMed ID: 31456520
[TBL] [Abstract][Full Text] [Related]
12. Precision Medicine for Advanced Pancreas Cancer: The Individualized Molecular Pancreatic Cancer Therapy (IMPaCT) Trial.
Chantrill LA; Nagrial AM; Watson C; Johns AL; Martyn-Smith M; Simpson S; Mead S; Jones MD; Samra JS; Gill AJ; Watson N; Chin VT; Humphris JL; Chou A; Brown B; Morey A; Pajic M; Grimmond SM; Chang DK; Thomas D; Sebastian L; Sjoquist K; Yip S; Pavlakis N; Asghari R; Harvey S; Grimison P; Simes J; Biankin AV; ;
Clin Cancer Res; 2015 May; 21(9):2029-37. PubMed ID: 25896973
[TBL] [Abstract][Full Text] [Related]
13. Clinical Utility of Circulating Tumor DNA for Molecular Assessment and Precision Medicine in Pancreatic Cancer.
Takai E; Totoki Y; Nakamura H; Kato M; Shibata T; Yachida S
Adv Exp Med Biol; 2016; 924():13-17. PubMed ID: 27753011
[TBL] [Abstract][Full Text] [Related]
14. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
15. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract][Full Text] [Related]
16. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer.
Hayashi H; Kohno T; Ueno H; Hiraoka N; Kondo S; Saito M; Shimada Y; Ichikawa H; Kato M; Shibata T; Morizane C; Sakamoto Y; Shimada K; Komatsu Y; Sakamoto N; Okusaka T
Pancreas; 2017 Mar; 46(3):335-340. PubMed ID: 28099251
[TBL] [Abstract][Full Text] [Related]
17. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
[TBL] [Abstract][Full Text] [Related]
18. Integrating Genomics Into Clinical Pediatric Oncology Using the Molecular Tumor Board at the Memorial Sloan Kettering Cancer Center.
Ortiz MV; Kobos R; Walsh M; Slotkin EK; Roberts S; Berger MF; Hameed M; Solit D; Ladanyi M; Shukla N; Kentsis A
Pediatr Blood Cancer; 2016 Aug; 63(8):1368-74. PubMed ID: 27082517
[TBL] [Abstract][Full Text] [Related]
19. Genetics and beyond: Precision Medicine Real-World Data for Patients with Cervical, Vaginal or Vulvar Cancer in a Tertiary Cancer Center.
Kraus FBT; Sultova E; Heinrich K; Jung A; Westphalen CB; Tauber CV; Kumbrink J; Rudelius M; Klauschen F; Greif PA; König A; Chelariu-Raicu A; Czogalla B; Burges A; Mahner S; Wuerstlein R; Trillsch F
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38397025
[TBL] [Abstract][Full Text] [Related]
20. Molecular tests and target therapies in oncology: recommendations from the Italian workshop.
Pinto C; Biffoni M; Popoli P; Marchetti A; Marchetti P; Martini N; Normanno N
Future Oncol; 2021 Sep; 17(26):3529-3539. PubMed ID: 34254524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
